Глава 4. Оптимизация гормонального фона

1. Canaris G. J., Manowitz N. R., Mayor G., Ridgeway E. G. (2000) The Colorado thyroid prevalence study // Arch of Int. Med (160): 526–534.

2. Svec F., Porter J. R. (1998) The actions of exogenous dehydroepiandrosterone in experimental animals and humans // Proceedings of the Society for Exp Bio and Med (218): 174–191.

3. Lemon J. A., Boreham D. R., Rollow C. D. (2003) A dietary supplement abolishes age-related cognitive decline in transgenic mice expressing elevated free radical processes // Exp Bio Med. (228): 800–810.

4. Butler R. N., Fossel M., Mitchell H., Heward C. B., Olshansky S. J., Perls T. T., Rothman D. J., Rothman S. M., Warner H. R., West M. D., and Wright W.F. (2002) Is there an anti-aging medicine? // J. of Gerontology Series A: Bio SciMed Sci (57): B333-B3385.

5. Straub R. H., Lehle K., Herfarth H., Weber M., Falk M. W., Preuner J., Scholmerich J. (2002) Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: Role of interleukin-6 and tumour necrosis factor // Eur J. Endo 146: 365–374.

6. National Sleep Foundation, “Epidemic of Daytime Sleepiness Linked to Increased Feelings of Anger, Stress, and Pessimism,” sleepfoundation.org/site/c.huIXKjM0IxF/b.2417359/k.3028/Epidemic_of_Daytime_Sleepiness_Linked_to_ Increased_Feelings_of_Anger_Stress_and_Pessimism.htm.

7. Leger D., Laudon M., Zisapel N. (2004) Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy // Am. J. Med. 116:91–95.

8. The Writing Group for the WHI Investigators (2002) Risks and benefits of estrogen plus progestin in healthy post-menopausal women: Principal results of the Women’s Health Initiative randomized controlled trial // JAMA 288 (3): 321–333.

9. The Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial // JAMA 291: 1701–1712.

10. Rossouw J. E., Prentice R. L., Manson J. E., Wu L., Barad D., Barnabei V. M., Ko M., LaCroix A. Z., et al. (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause // JAMA 297: 1465–1477.

11. Fournier A., Berrino F., Riboli E., Avenel V., and Clavel-Chapelon F. (2005). Риск развития рака молочной железы в связи с различными видами заместительной гормональной терапии в когорте E3N-EPIC // Проблемы репродукции. М.: Медиа Сфера, № 4 (2005).

12. Rudman D., Drinka P. J., Wilson C. R., Mattson D. E., Scherman F., Cuisinier M. C., Schultz S. (1994) Relations of endogenous anabolic hormones and physical activity to bone mineral density and lean body mass in elderly men // Clin Endo 40: 653–661.

13. Stephenson K., Price C., Kurdowska A., Neuenschwander P., Stephenson J., Pinson B., Stephenson D., Alfred D., Krupa A., Mahoney D., Zava D., and Bevan M. (2004) Topical progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women // ASH Annual Meeting Abstracts 104: 5318.